Press Releases

18 September 2017

Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial

Oxfordshire, UK, 18th September 2017 – Karus Therapeutics Ltd (‘Karus’), a leader in the design and development of innovative medicines with breakthrough potential in the treatment of cancer, today announced that the first patients have been dosed with its histone deacetylase 6 (HDAC6) inhibitor, KA2507, in a Phase I clinical study. This is the Company’s second orally-active small molecule cancer therapeutic agent to enter clinical trials during the past 12 months.

Read more

04 August 2017

Karus Therapeutics presenting at the CHI DoT 11th Annual Next-Generation Histone Deacetylase Inhibitors conference

Oxford, UK, 4 August 2017 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its COO/CSO will be delivering two presentations at the CHI DoT 11th Annual Kinase Inhibitor Discovery conference, Boston, 27 and 28 September 2017.

Read more

01 May 2017

Karus Therapeutics presenting at the 18th Annual Drug Discovery Summit/5th Annual Discovery Chemistry & Drug Design

Oxford, UK, 1 May 2017 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its Chief Scientific Officer will be delivering a presentation at the 18th Annual Drug Discovery Summit/5th Annual Discovery Chemistry & Drug Design Congress, Berlin, 13 June 2017.

Read more

21 October 2016

Karus Therapeutics presenting at BIO-Europe

Oxford, UK, 21 October 2016 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its CEO will be delivering a presentation at the 22nd BIO-Europe, Cologne, Germany, 7-9 November 2016.

Read more

05 October 2016

Karus Therapeutics Announces First Lymphoma Patients Dosed with KA2237 in Clinical Study at the MD Anderson Cancer Center

Oxford, UK, 5 October 2016 – Karus Therapeutics (‘Karus’), a leader in the development of innovative, orally-active medicines with breakthrough potential in the treatment of cancer, today announced that the first patients have been dosed in a Phase I study for its lead candidate, KA2237. 

Read more

03 October 2016

Karus Therapeutics giving lecture at BIO Investor

Oxford, UK, 3 October 2016 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its CEO will be delivering a lecture at the 15th Annual BIO Investor Forum, San Francisco, California, USA, 18-19 October 2016.

Read more

07 September 2016

Karus Therapeutics giving lecture at 10th Annual Symposium – Next Generation Histone Deacetylase Inhibitors

Oxford, UK, 7 September 2016 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced its CSO will be attending and delivering a lecture at the 9th Annual Kinase Inhibitor Discovery conference, Boston, USA, 19 September 2016.

Read more

01 September 2016

Karus Therapeutics delivering lecture at 9th Annual Kinase Inhibitor Discovery conference

Oxford, UK, 1 September 2016 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced its CSO will be attending and giving a lecture at the 9th Annual Kinase Inhibitor Discovery conference, Boston, USA, 21-22 September 2016.

Read more

21 April 2016

Karus Therapeutics presenting at BioEquity 2016

Oxford, UK, 21 April 2016 - Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer has announced that it will be giving a company presentation at BioEquity 2016, Copenhagen, Denmark, 10-11 May 2016.

Read more

29 March 2016

Karus Therapeutics presenting at AACR Annual Meeting 2016

Oxford, UK, 29 March 2016– Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced it will be giving a poster presentation at the AACR Annual Meeting in New Orleans, 16-20 April 2016.

Read more

21 March 2016

Karus Therapeutics presenting at BioTrinity 2016

Oxford, UK, 21 March 2016 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced that it will be giving a company presentation at BioTrinity 2016, London, UK, 25-27 April 2016.

Read more

01 March 2016

Karus Therapeutics presenting at Sachs 9th Annual European Life Science CEO Forum & Exhibition

Oxford, UK, 1 March 2016 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced that it will be presenting at Sachs 9th Annual European Life Science CEO Forum & Exhibition, Zurich, Switzerland, 15-16th March 2016.

Read more

10 December 2015

Karus Therapeutics Announces Strategic Collaboration with The University of Texas MD Anderson Cancer Center

Oxford, UK, 10 December 2015 – Karus Therapeutics (‘Karus’), a leader in the development of innovative medicines with breakthrough potential in the treatment of hematological cancers and solid tumor immunotherapy, today announced that it has entered into a strategic pre-clinical and clinical collaboration with The University of Texas MD Anderson Cancer Center. The collaboration will include both of Karus’s lead cancer candidates, KA2237 and KA2507.

 

Read more

07 December 2015

Karus Therapeutics presenting at the 4th Annual Cancer BioPartnering & Investment Forum

Oxford, UK, 7 December 2015 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced that Simon Kerry, Karus Therapeutics’ CEO will be giving a company presentation at the 4thAnnual Cancer BioPartnering & Investment Forum, New York, USA on the 24th February 2016.

Read more

30 November 2015

Karus Therapeutics presenting at the 8th Annual Biotech Showcase 2016

Oxford, UK, 30th November 2015 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced that Simon Kerry, Karus Therapeutics’ CEO will be giving a company presentation at the Biotech Showcase, San Francisco, USA, 11th-13th January 2016.

Read more

26 November 2015

Karus Therapeutics presenting at the 57th ASH Annual Meeting

Oxford, UK, 26th November 2015 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced that it will be giving a poster presentation at the 57th ASH Annual Meeting, Orlando, USA.

Read more

02 November 2015

Karus Therapeutics presenting at the EORTC-NCI-EMA-AACR Innovation and Biomarkers in Cancer Drug Development

Oxford, UK, 2 November 2015 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced that it will be giving a poster presentation at the EORTC-NCI-EMA-AACR Innovation and Biomarkers in Cancer Drug Development, Brussels, Belgium.  The conference will take place in 2016.

Read more

04 October 2015

Karus Therapeutics presenting AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oxford, UK, 4 October 2015 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced that it will be giving two poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 5-9 November 2015, Boston, USA

Read more

15 April 2015

Karus Therapeutics presenting at Sachs Immuno-oncology: BD&L and Investment Forum

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer and inflammatory disease, has announced that it will be presenting at Sachs Immuno-oncology: BD&L and Investment Forum, Chicago, USA, 29th May 2015.

Read more

18 March 2015

Karus Therapeutics presenting at AACR Annual Meeting 2015

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has announced that it will be giving two poster presentations at the AACR Annual Meeting in Philadelphia, 18–22 April 2015.

Read more

18 March 2015

Karus Therapeutics presenting at BioTrinity 2015

Simon Kerry, CEO of Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, will be attending and presenting at BioTrinity 2015, 11-13 May 2015 in Oxford, UK.

Read more

19 December 2014

Karus Therapeutics presenting at Biotech Showcase 2015

Dr Simon Kerry, CEO of Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, will be attending and presenting at Biotech Showcase 2015, 12-14 January 2015 in San Francisco.

Read more

21 October 2014

Karus Therapeutics Appoints New Head of Clinical Development and Head of Biology

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory diseases and cancer, today announced that it has further strengthened its R&D team with two new appointments; Dr Simon Roitt, who joins as Head of Clinical Development and Dr Peter Finan, who has been appointed as Karus’s Head of Biology.

Read more

29 September 2014

Karus Therapeutics presenting at NCRI Cancer Conference

Stephen Shuttleworth, CSO of Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, will be attending and presenting two posters at the 10th NCRI Cancer Conference, 2-5 November 2014 in Liverpool.

Read more

08 September 2014

Karus Therapeutics presenting at SACHS Biotech in Europe Forum

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has announced that Simon Kerry, CEO, will be presenting at the SACHS Biotech in Europe Forum, 30 September – 01 October, 2014 in Basel, Switzerland.

Read more